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Abstract: Dexamethasone (DEXA) is a potent immunosupressant and anti-inflammatory 
agent whose main side effects are muscle atrophy and insulin resistance in skeletal 
muscles. In this context, leucine supplementation may represent a way to limit the DEXA 
side effects. In this study, we have investigated the effects of a low and a high dose of 
leucine supplementation (via a bolus) on glucose homeostasis, muscle mass and muscle 
strength in energy-restricted and DEXA-treated rats. Since the leucine response may also 
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be linked to the administration of this amino acid, we performed a second set of 
experiments with leucine given in bolus (via gavage) versus leucine given via drinking 
water. Leucine supplementation was found to produce positive effects (e.g., reduced 
insulin levels) only when administrated in low dosage, both via the bolus or via drinking 
water. However, under DEXA treatment, leucine administration was found to significantly 
influence this response, since leucine supplementation via drinking water clearly induced a 
diabetic state, whereas the same effect was not observed when supplied via the gavage. 
Keywords: leucine supplementation; glucose homeostasis; skeletal muscle mass 
 
1. Introduction 
Branched-chain amino acids (BCAA—leucine, isoleucine and valine) supplementation, especially 
leucine, has been described as a potential therapeutic tool capable to attenuate skeletal muscle atrophy 
induced by several catabolic conditions, such as cancer, sepsis, muscular diseases [1] and 
glucocorticoid treatment [2]. Since leucine is considered as the second more potent insulin 
secretagogue amongst all the amino acids (AA) [3], it has been studied for its capacity to modulate 
whole body glucose homeostasis [4].  
Indeed, leucine supplementation might exert positive systemic effects in conditions characterized 
by increases in glucose homeostasis disturbance, such as high fat diet (HFD) induced insulin 
resistance, but the effects are controversial. For example, Zhang and coworkers [5] found increases in 
the glucose metabolism of leucine supplemented mice, whereas Lynch and coworkers [6] did not 
observe improvements nor decreases in the glucose homeostasis. However, this may have been due to 
the lack of standardization of doses and forms of administration. On the other hand, in healthy rats and 
humans, oral leucine feeding has shown to rapidly inhibit skeletal muscle protein degradation [7,8] and 
also promote robust increases in skeletal muscle protein synthesis [9], demonstrating overall a 
potential capacity to handle disturbances in glucose metabolism and spare skeletal muscle mass, 
especially under atrophic conditions [8]. However, its chronic effects remain elusive, specifically 
during insulin resistant states from different physiopathological backgrounds, such as glucocorticoid 
treatment (and even HFD treatment).  
Dexamethasone (DEXA) is a synthetic glucocorticoid form of the endogenous hormone cortisone, 
which exhibits potent immunosupressant and anti-inflammatory properties [10]. The successful 
therapeutic benefits of this drug in a wide range of inflammatory diseases is, however, limited as it 
presents several side effects [11], such as insulin resistance and skeletal muscle atrophy [12,13]. 
Therefore, in order to benefit from the desired effects of long term DEXA treatment, the deleterious 
responses must be reduced. In this context, leucine supplementation may represent an interesting 
intervention with a clinical perspective, due to the reasons justified from above.  
Since there is still a lack of evidence regarding the effects of leucine supplementation on  
DEXA-induced insulin resistance and skeletal muscle atrophy, we decided to investigate: (1) whether a 
supplementation, with a low dose of leucine (not capable of increasing insulin levels or muscle protein 
synthesis) or a high dose of leucine (capable of maximally increasing both insulin concentration and 
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muscle protein synthesis) given through gavage or drinking water is able to improve glucose 
metabolism, as well as spare the muscle mass and, consequently, voluntary muscular strength in 
healthy (control pair-fed and energy restricted) rats; (2) investigate to see if leucine supplementation 
via gavage or via drinking water exerts some positive effect on glucose metabolism and muscle 
sparing/strength effects under DEXA treatment; in other words, besides the dosage effect, would 
frequent nutritional stimuli (leucine provided through drinking water) be different from that provided 
by a pulsatile pattern (leucine provided through gavage) with both groups consuming the same  
daily dosage?  
2. Materials and Methods  
2.1. Animals 
The experiments were conducted in accordance with the National Research Council’s Guidelines 
for the Care and Use of Laboratory Animals. All methods used were approved by the Ethical 
Committee for Animal Research of the Physical Education and Sport of the University of Sao Paulo 
(protocol 2008/45). Adult male Wistar rats (mean body weight 440 g) were housed in individual cages 
under controlled environmental conditions (temperature, 22 °C; 12-h dark period) with a standard diet 
(Nuvilab, Brazil) and water provided ad libitum. 
2.2. Study 1 
Groups 
Animals were randomly divided into the following groups: control non-supplemented (CON-NS;  
n = 10), control + leucine low-dose (CON-LL; n = 10), control + leucine high-dose (CON-LH; n = 10), 
DEXA (DEX; n = 10), DEX + leucine low-dose (DEX-LL; n = 10) and DEXA + leucine high-dose 
(DEX-LH). During the duration of the experiment, which lasted seven days, DEXA (a synthetic 
glucocorticoid analogue that does not bind to plasma binding proteins) was given daily (at 9:00 a.m.) 
through intraperitoneal injection (5 mg/kg/day); control groups received an equivalent volume of 
saline (0.9% NaCl). As DEXA was reported to decrease food intake, all groups were fed the same 
amount of food (in terms of caloric intake) equal to the DEX group. Thus, differences among groups 
did not originate from different food intakes. We measured the caloric content of our standard chow 
(16.32 kJ/g) as well as leucine (25 kJ/g) in a calorimetric bomb (FTT Oxygen Bomb Calorimeter) in 
order to avoid differences in the caloric ingestion between experimental groups and observed that the 
total caloric consumption was not statistically different among groups. A suspension of 54.0 g of  
L-leucine/L in water was prepared according to Crozier and coworkers [9]. Rats of  
leucine-supplemented groups received 0.068 g/kg/day (low-dose) or 1.35 g/kg/day (high-dose) twice a 
day (8:00 a.m. and 2:00 p.m.) through gavage during seven days [9]. Importantly, the high dosage 
were capable of maximally increasing muscle protein synthesis and insulin plasmatic levels (in a well 
defined pulsatile form), whereas the low dosage was not capable of increasing either muscle protein 
synthesis or insulin plasmatic levels [9,14]. Non-supplemented groups received 0.155 mol/L of NaCl 
at a volume of 2.5 mL/100 g of body weight twice a day. This volume of saline is equivalent to the 
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volume of leucine suspension administered to leucine-supplemented groups and was chosen in order to 
take into account any possible volume-induced effects of oral gavage, i.e., gastric expansion-induced 
signaling. We chose to administer two daily doses of leucine in order to maintain plasma increased 
concentration throughout the day and counteract DEXA-induced effects. Animals were euthanized 
after 13 h fasting by decapitation. Soleus and extensor digitorius longus (EDL) muscles of each limb 
were isolated, weighed and frozen at −80 °C for analysis. To assess the dry over total weight ratio, a 
small portion of each muscle was weighed and then dried for 48 h.  
2.3. Study 2 
Since we observed that control groups responded equally to leucine supplementation via bolus or 
drinking water (data not shown), we additionally investigated whether or not leucine supplementation 
would be different via a bolus or drinking water in the presence of DEXA treatment.  
2.3.1. Groups  
Animals were randomly divided into the following groups: DEXA + leucine low-dose (DEX-LL;  
n = 8); DEXA + leucine low-dose drinking water (DEX-LL-H2O; n = 8); DEXA + leucine high-dose 
(DEX-LH; n = 8); and DEXA + leucine high-dose drinking water (DEX-LH-H2O; n = 8). The groups 
received the same dosage of DEXA administered in study 1. All groups were the same amount of food 
(in terms of caloric intake) equal to the DEXA group, and no statistically differences among groups 
were observed. DEX-LL and DEX-LH groups were supplemented via gavage (0.068 and  
1.35 g/kg/day, respectively) twice a day and fed the same diet with regular tap water as drinking water, 
as previously described in study 1. DEX-LL-H2O and DEX-LH-H2O groups were supplemented with 
leucine via drinking water, and the leucine dose was adjusted every day on the basis of drinking water 
intake the day before. The water or liquid leucine supplement was provided by means of graduated 
cylinders topped with a 1-hole rubber stopper holding a metal drinking nipple. Leucine in water 
solution was used as crystals grounded to a fine powder with a ceramic mortar and pestle to optimize 
solubility [15]. In this study, we added leucine in drinking water to compare leucine provided through 
gavage (which results in a well defined pulsatile pattern [9,14]) versus leucine provided through 
drinking water (rendering less fluctuations in the leucine levels) with both groups consuming the same 
daily dosage. Animals were euthanized by decapitation and soleus, and EDL muscles of each limb 
were isolated, weighed and frozen at −80 °C for analysis.  
2.3.2. Basal Fasting Glucose, Insulin and Tryacilglycerol (TAG) Levels 
Basal and fed glycemia were measured through blood collected from the caudal vein after an 
overnight fast (13 h) using a digital glucometer (ACCU-CHEK Performa, Roche) before euthanasia. 
Immediately after euthanasia (13 h fasting), blood was collected and serum samples were prepared on 
ice. Serum was frozen and stored at −80 °C for analysis. Basal TAG was measured using a commercial 
kit (Biolab, Brazil). Serum insulin concentration was quantified using the commercial kits RIA  
(DPC
®
, Brazil). The homeostase model for assessment of insulin resistance index (HOMA-IR) was 
calculated as follows:  
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HOMA-IR index (mmol·mU/L
2
) = fasting insulin (mU/L) × serum glucose (mmol/L)/22.5 [16]. 
2.3.3. Motor Performance Tests 
In order to evaluate skeletal muscle function, two evaluations were carried out. Such evaluations are 
widely adopted as measures of muscle function in dystrophic mice. The first one, the Grip Strength 
System Test (model: DFE-002, San Diego Instruments, San Diego, CA, USA) is a condition where 
animals are let to grab onto the system with the forepaws as the experimenter gently pulls on their 
tails. This allows the experimenter to determine the maximal strength before the animal releases the 
bar [17]. Importantly, all measurements of maximal strength were performed by the same investigator, 
who was highly experienced with performing this test. 
The second motor performance test is the ambulation test. This test allows the determination of the 
mean length of a step measured in hindfoot ink prints and is normalized by the animal’s length. 
Briefly, rats were allowed to freely run in a corridor (length, 100 cm; width, 10.5 cm; height of lateral 
walls, 20 cm) three different times. Before the test, the animals were permitted to explore the  
apparatus [18,19]. Mean values were individually calculated for each test through the mean of three 
consecutive tests performed during one minute. 
2.3.4. RNA Isolation and Realt-Time PCR 
Total RNA was extracted from homogenized soleus and EDL muscles with the Trizol reagent 
(Invitrogen) according to the manufacturer instructions. One microgram of total RNA was 
retranscribed with MMLV enzyme (Invitrogen), and an aliquot was used to measure real-time PCR. 
All reactions were conducted in a volume of 25 µL containing 4 mM MgCl2 (Invitrogen), 0.25 mM 
dNTPs (Invitrogen), 1.2 U of Taq polymerase (Invitrogen), 1/30000 Sybr Green (Invitrogen) and 
specific oligonucleotides for each gene with the Rotor Gene 3000 sequence detector (Quiagen Inc.; 
Hilden, Germany). Primers utilized for real-time PCR analysis was: GLUT-4 sense:  
5′-GGGCTGTGAGTGAGTGCTTTC-3′; antisense: 5′-CAGCGAGGCAAGGCTAGA-3′; GAPDH 
sense: 5′-GATGGGTGTGAACCACGAGAAA-3′; antisense: 5′-ACGGATACATTGGGGGTAGGA-3′. 
Reactions were run for 40 cycles under the following conditions: 40 s at 95 °C, 40 s at 65 °C and 40 s 
at 72 °C. The amplification of unique products in each reaction was verified by melting curve and 
ethidium bromide (Sigma Aldrich) stained agarose gel electrophoresis. Each sample was run in 
triplicate. The expression level of each gene was normalized to housekeeping gene (GAPDH) 
expression level using the standard curve method. Mean and standard errors were calculated and are 
expressed as fold changes relative to the control group. 
2.3.5. Statistical Analysis 
The dependent variables were tested by either one-way or two-way ANOVA, as appropriate.  
A post-hoc test with a Tukey adjustment was performed for multiple comparison purposes. The 
significance level was set at p < 0.05. The results are expressed as means ± S.E.M.  
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3. Results 
3.1. Study 1 
The effects of DEXA treatment and leucine supplementation on body weight and muscle 
morphological parameters: as shown in Table 1, the baseline body weight was similar among groups. 
All groups were characterized by a significant body weight reduction at the end of the experimental 
protocol (p < 0.05). DEXA-treated groups showed significantly reduced body weight when compared 
with the control groups (p < 0.05). Thus, leucine supplementation at both low and high doses did not 
counteract body weight loss in both food restricted (control groups) and DEXA-treated animals. Soleus 
muscle mass did not differ among groups. Leucine supplementation at high doses attenuated food  
restriction-induced EDL muscle loss (CON-LH group) when compared with the CON-NS group  
(p < 0.05). All DEXA-treated animals presented reduced EDL muscle mass when compared with the 
CON-NS group (p < 0.05), and leucine supplementation at both low and high doses of amino acid did 
not attenuate it (total n = 60). 
Table 1. Body and muscle morphological parameters of the experimental groups. 
Variable 
Group 
CON-NS CON-LL CON-LH DEX-NS DEX-LL DEX-LH 
Initial BW (g) 442.7 ± 5.90 442.2 ± 4.91 441.0 ± 4.35 443.8 ± 6.19 443.3 ± 4.19 444.8 ± 6.16 
Final BW (g) 381.9 ± 22.1 
b
 386.3 ± 20.32 
b
 375.0 ± 10.21 
b
 343.4 ± 11.53 
a,b
 345.79 ± 15.89 
a,b
 339.9 ± 11.73 
a,b
 
Delta BW (g) −60.8 ± 4.64 −55.9 ± 5.36 −65.17 ± 4.98 −100.8 ± 2.40 a −103.6 ± 2.08 a −104.5 ± 3.35 a 
Soleus (mg) 214.8 ± 5.99 223.3 ± 5.45 221.0 ± 6.13 214.4 ± 4.29 210.8 ± 2.25 212.7 ± 5.45 
EDL (mg) 189.4 ± 2.31 197.3 ± 2.08 200.1 ± 1.49 
a
 179.6 ± 3.37 
a
 174.8 ± 2.80 
a
 174.6 ± 4.12 
a
 
Values are expressed as mean ± SE. Control non-supplemented group (CON-NS; n = 10); Control leucine supplemented 
group with low dose via gavage (CON-LL; n = 10); Control leucine supplemented group with high dose via gavage 
(CON-LH; n = 10); DEXA non supplemented group (DEX-NS; n = 10); DEXA treated group plus low dose of leucine 
supplementation via gavage (DEX-LL; n = 10); DEXA treated group plus high dose of leucine supplementation via 
gavage (DEX-LH; n = 10). BW—body weight; EDL—extensor digitorum longus. a p < 0.05 vs. CON-NS; b p < 0.05 vs. 
Initial BW. 
The effects of DEXA treatment and leucine supplementation on water intake: In the control groups, 
water intake was significantly increased in CON-LL group when compared with the CON-NS group at 
day 3 (38.33 ± 0.57 in CON-LL group vs. 29.00 ± 2.93 in CON-NS group; p < 0.05). At day 6 of 
treatment, DEX-NS group showed increased water intake when compared with day 1 (36.77 ± 2.34 in 
DEX-NS group at day 6 vs. 28.09 ± 2.05 at day 1; p < 0.05) and with the CON-NS group at day 6 
(27.53 ± 2.68 in CON-NS group at day 6; p < 0.05). DEX-LL group presented reduced water intake at 
day 3 when compared with day 1 (23.14 ± 1.04 in DEX-LL group at day 3 vs. 31.2 ± 2.05 at day 1;  
p < 0.05) and increased when compared with the CON-NS group at day 6 (p < 0.05) (total n = 60). 
The effects of DEXA treatment and leucine supplementation on serum glucose, insulin and 
triacylglycerol (TAG): fasting glycemia and tryacilglycerol were significantly higher in the DEX-NS 
group when compared with the CON-NS group (Figure 1A; 166.6 ± 20.8 mg/dL in DEX-NS vs.  
118.5 ± 7.5 mg/dL in CON-NS group; p < 0.05; Figure 1C; 114.4 ± 14.4 mg/dL in DEX-NS vs.  
68.3 ± 9.7 mg/dL in CON-NS group; p < 0.05), suggesting a DEXA-induced increase in blood glucose 
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and TAG. Leucine supplementation at a low dose decreased fasting insulin and triacylglycerol when 
compared to the CON-NS and CON-LH groups (0.15 ± 0.01 mg/dL in CON-LL vs. 2.95 ± 0.66 mg/dL 
in CON-NS and 2.68 ± 0.79 mg/dL in CON-LH groups; p < 0.05; Figure 1B; 27.56 ± 2.89 mg/dL in 
CON-LL vs. 68.31 ± 9.74 mg/dL in CON-NS group; p < 0.05; Figure 1C). DEX-LL and DEX-LH 
groups presented increased fasting glycemia (157.6 ± 29.8 mg/dL in DEX-LL vs. 103.3 ± 4.0 mg/dL in 
CON-LL group; p < 0.05; 190.1 ± 27.2 mg/dL in DEX-LH vs. 96.7 ± 3.2 mg/dL in CON-LH group;  
p < 0.05; Figure 1A), insulin (3.54 ± 0.74 mg/dL in DEX-LL vs. 0.15 ± 0.01 mg/dL in CON-LL group; 
p < 0.05; 4.42 ± 0.51 mg/dL in DEX-LH vs. 2.68 ± 0.79 mg/dL in CON-LH group; p < 0.05;  
Figure 1B) and triacylglycerol (122.4 ± 16.9 mg/dL in DEX-LL vs. 27.6 ± 2.9 mg/dL in CON-LL 
group; p < 0.05; 119.7 ± 32.7 mg/dL in DEX-LH vs. 38.5 ± 4.7 mg/dL in CON-LH group; p < 0.05; 
Figure 1C) when compared to its respective control groups. Thus, it is possible to emphasize that these 
effects were meditated by leucine since both groups had the same food intake (n = 10 per group). 
Figure 1. Fasting (A) blood glucose, (B) insulin, and (C) triacylglycerol levels and  
(D) HOMA index. Values are expressed as mean ± S.E.M. 
a
 Different from CON-NS  
(p < 0.05); 
b
 Different from CON-LL (p < 0.05); and 
c
 Different from CON-LH (p < 0.05). 
 
In the fed state, control groups did not show any significant alteration in serum glucose during the 
experimental protocol. However, DEXA-treated groups showed markedly increased serum glucose 
levels at days 3 and 6 when compared with day 1 (p < 0.05) and with the CON-NS group at days 3 and 
6 (p < 0.05). No significant differences were observed among DEXA-treated groups (Table 2)  
(n = 10). 
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Table 2. Fed serum glucose (mg/dL) of the experimental groups on days 1, 3 and 6 of the study. 
Day 
Group 
CON-NS CON-LL CON-LH DEX-NS DEX-LL DEX-LH 
1 110.5 ± 5.73 107.3 ± 0.76 115.5 ± 1.47 120.1 ± 5.06 104.8 ± 4.07 114.7 ± 4.78 
3 109.8 ± 5.26 103.5 ± 1.16 129.6 ± 1.28 215.6 ± 29.08 
a,b
 196.5 ± 17.27 
a,b
 178.1 ± 15.18 
a,b
 
6 109.8 ± 5.26 110.0 ± 1.64 130.7 ± 2.25 267.3 ± 31.51 
a,b
 255.2 ± 23.44 
a,b
 215.6 ± 22.33 
a,b
 
Values are expressed as mean ± SE. Control non-supplemented group (CON-NS; n = 10); Control leucine supplemented 
group with low dose via gavage (CON-LL; n = 10); Control leucine supplemented group with high dose via gavage 
(CON-LH; n = 10); DEXA non supplemented group (DEX-NS; n = 10); DEXA treated group plus low dose of leucine 
supplementation via gavage (DEX-LL; n = 10); DEXA treated group plus high dose of leucine supplementation via 
gavage (DEX-LH; n = 10). a p < 0.05 vs. CON-NS in the same day of treatment; b p < 0.05 vs. day 1 in the same group. 
The effects of DEXA treatment and leucine supplementation on GLUT-4 gene expression in 
skeletal muscle: in soleus muscle, GLUT-4 gene expression was not significantly affected by DEXA 
or leucine treatment. In EDL muscle, however, GLUT-4 mRNA content was significantly lower in 
DEX-NS, DEX-LL and DEX-LH groups (0.69 ± 0.38, 0.63 ± 0.18 and 0.54 ± 0.17, respectively) when 
compared to CON-NS group (1.00 ± 0.15; p < 0.05; Figure 2A). In control supplemented groups, only 
CON-LL was lower than CON-NS (0.60 ± 0.16 vs. 1.00 ± 0.15; p < 0.05; Figure 2B) (n = 6–8 animals  
per group). 
Figure 2. GLUT-4 gene expression in (A) soleus and (B) EDL muscles Values are 
expressed as mean ± S.E.M. a Different from CON-NS (p < 0.05). 
 
The effects of DEXA treatment and leucine supplementation on muscle functional parameters: We 
observed that DEX-LH animals presented a modest but significant deficit in mean ambulation when 
compared to the CON-LH group (0.54 ± 0.03 cm in DEX-LH vs. 0.59 ± 0.02 cm in CON-LH group;  
p < 0.05; Figure 3B). The CON-LH group also presented less mean grip strength when compared with 
the CON-LL group (0.46 ± 0.04 N in CON-LH vs. 0.66 ± 0.02 N in CON-LL; p < 0.05; Figure 3D)  
(n = 8–10 per group). 
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Figure 3. Muscle functional parameters. (A) Maximum ambulation (cm); (B) Mean 
ambulation (cm); (C) Maximum grip strength (N); (D) Mean grip strength (N). Values are 
expressed as mean ± S.E.M. a Different from CON-NS (p < 0.05); b Different from CON-LL 
(p < 0.05); and c Different from CON-LH (p < 0.05). 
 
3.2. Study 2 
The effects of DEXA treatment and leucine supplementation on body weight and muscle 
morphological parameters: baseline body weight did not differ among groups. Leucine supplementation 
with a high dose via drinking water (DEX-LH (H2O) group) significantly attenuated body weight loss 
when compared with the DEX-LL and DEX-LH (bolus) groups (p < 0.05). Soleus muscle mass was 
significantly reduced in DEX-LL (H2O) group when compared with the DEX-LL (bolus) and DEX-LH 
groups (p < 0.05). EDL muscle mass did not significantly differ among groups (Table 3). 
Table 3. Body and muscle morphological parameters of the experimental groups. 
Variable 
Group 
DEX-LL DEX-LL (H2O) DEX-LH DEX-LH (H2O) 
Initial BW (g) 442.3 ± 1.40 441.8 ± 1.58 444.9 ± 1.49 446.7 ± 1.27 
Final BW (g) 338.9 ± 1.83 346.5 ± 3.58 340.0 ± 2.93 361.0 ± 4.13 
a,b,c
 
Delta BW (g) −103.6 ± 2.07 −95.27 ± 3.14 −104.5 ± 3.35 −85.67 ± 6.77 a,b 
Soleus (mg) 222.5 ± 5.28 205.0 ± 2.39 
a,b
 222.9 ± 5.54 207.4 ± 3.22 
EDL (mg) 174.8 ± 2.79 170.5 ± 1.99 174.6 ± 4.12 169.4 ± 1.27 
Values are expressed as mean ± SE. DEXA treated group plus low dose of leucine supplementation via gavage (DEX-LL; 
n = 10); DEXA treated group plus low dose of leucine supplementation via drinking water (DEX-LL (H2O); n = 10); 
DEXA treated group plus high dose of leucine supplementation via gavage (DEX-LH; n = 10). DEXA treated group plus 
high dose of leucine supplementation via drinking water (DEX-LH (H2O); n = 10). BW—body weight; EDL—extensor 
digitorum longus. a p < 0.05 vs. DEX-LL; b p < 0.05 vs. DEX-LH; c p < 0.05 vs. DEX-LL (H2O). 
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The effects of DEXA treatment and leucine supplementation on water intake: both DEX-LL (H2O) 
and DEX-LH (H2O) presented increased water intake at day 6 when compared with their intake at  
day 1 (48.80 ± 3.45 in DEX-LL (H2O) group at day 6 vs. 31.44 ± 3.09 at day 1; p < 0.05; 45.29 ± 1.84 
in DEX-LH (H2O) group at day 6 vs. 34.25±2.93 at day 1; p < 0.05) and with the DEX-LL and DEX-LH 
at day 6 (34.67 ± 2.34 in DEX-LL group and 26.56 ± 3.98 in DEX-LH group at day 6; p < 0.05). The 
DEX-LH (H2O) group showed increased water intake when compared with the DEX-LL and DEX-LH 
groups at day 3 (33.08 ± 1.7 in DEX-LH (H2O) group vs. 23.14 ± 1.04 in DEX-LL group and  
22.00 ± 1.98 in DEX-LH group; p < 0.05). 
The effects of DEXA treatment and leucine supplementation on serum glucose, insulin and 
triacylglycerol (TAG): fasting serum glucose was significantly increased in the DEX-LL (H2O) group 
when compared with the DEX-LL group (320.3 ± 68.4 mg/dL in DEX-LL (H2O) group vs.  
173.6 ± 28.2 mg/dL in DEX-LL group; p < 0.05; Figure 4A) and in the DEX-LH (H2O) when 
compared with the DEX-LH group (338.7 ± 41.9 mg/dL in DEX-LH (H2O) group vs. 176.1 ± 21.4 mg/dL 
in DEX-LH group; p < 0.05; Figure 4A). These results suggest a dose-response and administration 
route action of leucine. The DEX-LH (H2O) group also presented decreased fasting serum insulin 
when compared with the DEX-LH group (35.24 ± 18.94 mg/dL in DEX-LL (H2O) group vs.  
109.3 ± 12.00 mg/dL in DEX-LL group; p < 0.05; Figure 4B). Regarding fasting triacylglycerol,  
DEX-LL (H2O) presented increased level when compared with the DEX-LL group (182.3 ± 37.1 mg/dL 
in DEX-LL (H2O) group vs. 72.2 ± 31.6 mg/dL in DEX-LL group; p < 0.05; Figure 4C). HOMA-IR 
index did not significantly differ among groups (Figure 4D). 
Figure 4. Fasting (A) blood glucose, (B) insulin and (C) triacylglycerol levels and  
(D) HOMA index. Values are expressed as mean ± S.E.M. a Different from DEX-LL 
(Bolus) (p < 0.05); b Different from DEX-LL (H2O) (p < 0.05); and 
c
 Different from DEX-LH 
(Bolus) (p < 0.05). 
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At days 3 and 6 of the experiment (with the notable exception of the DEX-LH group at day 3), all 
groups presented markedly increased serum glucose level in the fed state when compared with their 
respective day 1 (p < 0.05). DEX-LL (H2O) and the DEX-LH (H2O) groups showed higher serum 
glucose level in the fed state when compared with the DEX-LH group at day 6 (p < 0.05; Table 4), 
suggesting that the route of administration promoted distinct results on blood glucose (n = 10). 
Table 4. Fed serum glucose (mg/dL) of the experimental groups on days 1, 3 and 6 of the study. 
Day 
Group 
DEX-LL DEX-LL (H2O) DEX-LH DEX-LH (H2O) 
1 104.8 ± 4.07 100.2 ± 4.14 114.7 ± 4.78 100.3 ± 4.95 
3 196.5 ± 17.27 
b
 175.4 ± 9.49 
b
 178.1 ± 15.18 177.4 ± 10.16 
b
 
6 255.2 ± 23.44 
b
 286.1 ± 37.34 
a,b
 215.6 ± 22.33 
b
 314.8 ± 39.34 
a,b
 
Values are expressed as mean ± SE. DEXA treated group plus low dose of leucine supplementation via 
gavage (DEX-LL; n = 10); DEXA treated group plus low dose of leucine supplementation via drinking water 
(DEX-LL (H2O); n = 10); DEXA treated group plus high dose of leucine supplementation via gavage  
(DEX-LH; n = 10). DEXA treated group plus high dose of leucine supplementation via drinking water  
(DEX-LH (H2O); n = 10). 
a
 p < 0.05 vs. DEX-LH in the same day of treatment; 
b
 p < 0.05 vs. day 1 in the  
same group. 
The effects of DEXA treatment and leucine supplementation on GLUT-4 gene expression in skeletal muscle: 
no significant differences were recorded in GLUT-4 gene expression among groups (Figure 5; p > 0.05). 
Figure 5. GLUT-4 gene expression in (A) soleus and (B) EDL muscles. Values are 
expressed as mean ± S.E.M. 
 
The effects of DEXA treatment and leucine supplementation on muscle functional parameters: no 
significant difference was observed in maximum ambulation, mean ambulation, maximum grip 
strength and mean grip strength among groups (n = 8–10). 
4. Discussion 
The major findings of the present study are that under DEXA treatment, leucine supplementation 
through gavage in both low and high doses was not capable of changing metabolic parameters  
(i.e., triacylglycerol, fasting insulin levels and fasting glucose levels), but was capable of decreasing 
maximal voluntary strength function. On the other hand, when administered to leucine supplementated 
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rats via drinking water and under DEXA treatment, even at low dosages, it was capable of inducing a 
massive diabetic state (and also decreasing the EDL mass), when compared with leucine supplemented 
rats via gavage, even at low doses. This result clearly demonstrates that not only the daily dosage, but 
also the administration form and leucine kinetics of this supplement are important players to be 
considered under DEXA treatment induced insulin resistance. 
As previously described, leucine supplementation has been shown to spare skeletal muscle mass 
during several atrophic states, including insulin resistance [5]. Recently, it was demonstrated that 
supplementation with 0.6 g/kg of body mass of BCAA (46% leucine, 28% valine and 23% isovaline) 
was capable to attenuate the soleus muscle atrophy induced by DEXA (0.6 mg/kg given 
intraperitoneally—I.P., during 5 days) in Sprague Dawley rats [2]. However, in the same study, the 
authors did not report any information regarding insulin resistance. On the other hand, in our study, we 
chose the dosage of 5 mg DEXA/kg of body mass, since 1 mg/kg of body mass was unable to induce 
measurable skeletal muscle atrophy in our Wistar rats (data not shown). Moreover, when compared to 
previous studies of our group also using Wistar rats, DEXA given I.P. compared to DEXA given via 
drinking water [20], DEXA I.P. was slightly superior in increasing fasting glucose levels and inferior 
in inducing skeletal muscle atrophy [20]. From the above information, we conclude that: (1) glucose 
metabolism should be evaluated together with the possible sparing effect of leucine supplementation 
under glucocorticoid treatment; and (2) the administration pathway exerts a determinant effect on the 
magnitude of decrements in glucose homeostasis and skeletal muscle atrophy, not necessarily linked to 
each other. 
As stated before, our major expectation was that leucine supplementation in low versus high 
dosages, due to its different physiological effects, would be capable of inducing profound changes in 
glucose homeostasis parameters, as well as skeletal muscle atrophy in both treated and non-treated 
DEXA groups. In fact, our expectation was that low dosages (due to the fact of non stimulating insulin 
secretion) [9] would be beneficial to DEXA treated rats, because glucose metabolism is already 
profoundly affected by glucocorticoid treatment. On the other hand, in energy restricted healthy rats, 
we were confident that high dosages would be better, because data from the literature suggests that 
higher leucine dosages would be more effective at decreasing muscle proteolysis [8]. Surprisingly, 
leucine supplementation offered via gavage was innocuous to glucose homeostasis and skeletal muscle 
mass under DEXA treatment in both low and high doses. This result demonstrated the capacity of the 
whole body to deal with low and even very high amounts of leucine administered as a bolus, which is 
somewhat surprising, because leucine, especially in high amounts, is capable of modifying insulin 
secretion (and consequently glucose uptake by peripheral tissues) and induces skeletal muscle protein 
synthesis, while decreasing muscle proteolysis [1,8,9,20]. Following the same line of reasoning and 
contrariwise to our initial hypothesis, in the healthy group (non DEXA treated group), both low and 
high doses showed similar effects on skeletal muscle atrophy. However, serum glucose, fasting insulin 
concentrations and also HOMA-IR index significantly decreased, suggesting an improvement in 
glucose metabolism in the low dose leucine supplemented group, which could be of clinical 
significance during weight loss diets, as suggested by Layman [21]. This result could explain why 
BCAA supplementation, in addition to dexamethasone treatment, was so effective in the treatment of 
skeletal muscle atrophy in the study conducted by Yamamoto and coworkers [2]. Interestingly, in a 
study of mice consuming high fat diet, the consumption of a chow containing 20% protein (with 1.5% 
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leucine in w/v) increased oxygen consumption (and increasing resting energy expenditure) [5], and in 
C2C12 myocytes, leucine (0.5 mM) increased mitonchondrial mass by 30% and stimulated genes 
related to mitochondrial biogenesis [22]. Additionally, only leucine supplementation was able to 
protect animals from the deleterious effects of a high fat diet, such as insulin resistance and increased 
LDL cholesterol [5]. Although not directly measured in our study, we also observed a decrease in the 
blood TAG concentration in the low dose control group. 
We then undertook a second study comparing the effects of DEXA plus leucine treatment with low 
and high doses of this amino acid used via bolus, as previously described, against the same daily 
concentration offered in the drinking water. Since the dosage effect was not different when comparing 
rats presenting insulin resistance mediated by DEXA treatment as shown in Figure 1A, would frequent 
nutritional stimuli be different from that provided by a pulsatile pattern to aggravate insulin resistance 
caused by DEXA treatment? 
To test this hypothesis, we supplemented four groups of DEXA-treated rats, which consumed the 
same daily dose: the first two groups consumed the low dose of leucine in a pulsatile form (via gavage) 
versus a non-pulsatile form (via drinking water), and the second two groups followed the same 
schedule but consumed the high dosage. Our results were notable: rats supplemented through short 
periods of time (offered in drinking water), in a non-pulsatile form presented a markedly higher fasting 
glycemia compared with rats supplemented with the same daily dosage, in a pulsatile form  
(Figure 4A). These results suggest that tissues need time to terminate the leucine signal. Moreover, 
these results show that the continuous presence of this AA in the whole body, in an DEXA-induced 
insulin resistant state, would be capable of transforming to a clear diabetes state even with such a small 
leucine dose (i.e., not capable of affecting glucose homeostasis when supplied via bolus). Importantly, 
this outcome also occurred in the high dosage group, which proves that the threshold of leucine 
supplementation capable of inducing diabetes, in a previous DEXA-induced insulin resistance, is 
extremely low when supplied via drinking water; this would be a completely novel result. On the 
contrary, the results clearly demonstrated that leucine supplementation with low dose via drinking 
water did not modify muscle mass of DEXA-treated animals when compared with gavage and the 
same pattern was observed with a high dose of leucine. This would mean that skeletal muscle at our 
end point, would not suffer the effects of this disturbance on glucose homeostasis. In fact, as shown 
below, GLUT-4 gene expression was unaltered in the muscles analyzed in this study. Interestingly, 
leucine supplementation (1.5% in drinking water for eight months) carried out in the polygenic mouse 
model NONcNZO10/LtJ (RCS10), which is predisposed to beta cell failure and type 2 diabetes, is able 
to improve the glycemic control that was associated with an increased insulin response to food 
challenge in control mice [23]. In our study, in the presence of DEXA plus high doses of leucine in the 
drinking water, we observed a significant decrease in the insulin level measured in fasted animals. 
Such a decrease may be associated with a failure of the beta cells to respond to high leucine 
concentration for insulin secretion in this group of animals. However, such an effect was not observed 
in the control animals supplemented with high leucine dose. Although insulin levels decreased in both 
situations, these results would indicate diametrically opposite situations. Under healthy conditions, a 
low dose of supplemented leucine would be capable of increasing glucose homeostasis and reducing 
insulin plasmatic levels. On the other hand, when given chronically at low and high doses in the 
presence of DEXA-induced insulin resistance, leucine supplementation promotes a clear diabetic state, 
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and the diminishment of insulin levels observed with high doses would indicate a beta cell failure 
function. However, this hypothesis needs further research in order to be confirmed. 
In muscle cells, glucose transport is mainly controlled by the stimulation of insulin, leading to the 
translocation of GLUT-4 from late and early endosome vesicles to the plasmatic membrane, as well as 
through control of gene expression. Indeed, multiple and complex mechanisms control the GLUT-4 
transporter function [24]. In addition, it is acknowledged that DEXA treatment affects several steps of 
the insulin signaling cascade, leading to impaired glucose transport inside muscle cells [13]. However, 
there is very little information about the involvement of leucine supplementation in DEX-treated 
animals on GLUT-4 gene expression in different muscle tissues. 
In study 1, we detected in EDL muscles a marked impairment of GLUT-4 gene expression in 
DEXA treated groups (Figure 2). EDL muscles are primarily composed of fast twitch muscle  
fibers [25]. This result may be linked with the modification of the genomic expression that can lead to 
impaired glucose transport [10,24]. This would mean that during conditions of supplementation with 
high doses of leucine and in short term periods, GLUT-4 expression is strongly controlled by hormonal 
inputs. In order to test such a concept, we compared in study 2 the effect of leucine supplementation in 
DEXA treated animals (Figure 5). The results obtained are compatible with the idea that with high 
doses of leucine in short-term periods, GLUT-4 expression is mainly controlled by hormonal inputs, 
not genetic ones. For example, Hu and coworkers [12] recently showed that under insulin resistant 
conditions (e.g., stressed rats showing increased glucocorticoid levels), the cortisol receptor binds to 
and inactivates the insulin receptor, demonstrating the strong impact of glucocorticoids during periods 
of insulin resistance on cell signaling. In another study by Doi and coworkers [26] examining the 
effects of isoleucine, the investigators found in C2C12 cells that the isoleucine effect on glucose uptake 
was mediated by phosphatidylinositol 3-kinase (PI3K). These results suggest that isoleucine stimulates 
the insulin-independent glucose uptake in skeletal muscle cells, which may contribute to the plasma 
glucose-lowering effect of isoleucine in normal rats. Collectively, our results suggest that healthy adult 
rats are capable of metabolizing very high amounts of leucine, and that the threshold of leucine 
supplementation needed to transform a protein synthesis signal into an insulin-resistant one is very 
high during normal states, but abnormal under glucocorticoid induced insulin resistance states, 
especially when supplied via drinking water. 
The role of leucine supplementation in this scenario is uncertain because, when compared with 
Control-NS group, only Control-LL group showed a decreased GLUT-4 expression, and this decrease 
is evidenced only in the EDL muscle (Figure 2B). This result points out that GLUT-4 gene expression 
in EDL muscles may be altered not only by DEX treatment, but also by leucine supplementation, 
although this parameter is not predictive of changes in the whole body glucose metabolism and 
additional measurements, such as total GLUT-4, membrane-bound and glucose uptake in isolated 
muscles should provide more conclusive results. 
Finally, when we evaluated the muscle function of these animals, we observed that animals treated 
with DEXA and receiving high dose of leucine presented a significant reduction in mean ambulation 
when compared with the control group. Surprisingly, control animals supplemented with high doses of 
leucine also presented lower mean grip strength when compared with the low dose group, suggesting 
that a high leucine dose, applied via bolus, is not innocuous in this experimental model after seven 
days of treatment. 
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5. Conclusions  
These results show that the continuous presence of this AA in the whole body, in an insulin 
resistant state (DEXA-induced), would have several clinical implications: (1) will the results of 
prolonged leucine plus DEXA treatment in muscle cells (in a non-pulsatile form) apply to the whole 
body measurement? (2) Will patients receiving intravenous nutrition, but suffering from  
insulin-resistant states (induced by glucocorticoid treatment), benefit from AA supplementation?  
(3) Will skeletal muscle cells treated with glucocorticoids and essential AA have the same capacity to 
metabolize AA and glucose? (4) Are subjects that have resistance to insulin (due to overstress and 
hypercortisolemia induced stress) as showed by Hu and coworkers [12] and are ingesting several meals 
containing high amounts of protein (and leucine) per day capable of maintaining muscle mass and 
strength during these conditions? The answers to such questions are still unknown, and until further 
research clarifies the issue, the pros and cons will have to be weighed for each individual case. 
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